Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weibing I
- Development stage
- Phase 1
- Lead developer
- Beijing Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Weibing I is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University. It is used as part of a syndrome-differentiation-based therapeutic approach for functional dyspepsia. In this clinical framework, Weibing I is typically prescribed for patients exhibiting specific TCM patterns, such as spleen-stomach deficiency-cold, to regulate gastrointestinal function and alleviate symptoms like epigastric pain and bloating. It was evaluated in a Phase 1 clinical trial (ChiCTR-TRC-10001074) alongside other numbered Weibing formulas (II, III, and IV) to validate the efficacy of pattern-based TCM treatment in dyspeptic patients.
Beyond the preview
Go deeper on Weibing I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Weibing I.